Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis. Issue 1 (3rd January 2021)
- Record Type:
- Journal Article
- Title:
- Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis. Issue 1 (3rd January 2021)
- Main Title:
- Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis
- Authors:
- Das, Manoja Kumar
Arora, Narendra Kumar
Poluru, Ramesh
Tate, Jacqueline E.
Gupta, Bini
Sharan, Apoorva
Aggarwal, Mahesh K.
Haldar, Pradeep
Parashar, Umesh D
Zuber, Patrick L.F.
Bonhoeffer, Jan
Ray, Arindam
Wakhlu, Ashish
Vyas, Bhadresh R.
Iqbal Bhat, Javeed
Goswami, Jayanta K.
Mathai, John
K., Kameswari
Bharadia, Lalit
Sankhe, Lalit
M.K., Ajayakumar
Mohan, Neelam
Jena, Pradeep K.
Sarangi, Rachita
Shad, Rashmi
Debbarma, Sanjib K.
J., Shyamala
Ratan, Simmi K.
Sarkar, Suman
Kumar, Vijayendra
Maure, Christine G.
Dubey, Anand P.
Gupta, Atul
Sam, Cenita J.
Mufti, Gowhar Nazir
Trivedi, Harsh
Shad, Jimmy
Lahiri, Kaushik
R, Krishnaswamy
Luthra, Meera
Behera, Narendra
P, Padmalatha
G., Rajamani
Kumar, Rakesh
Sarkar, Ruchirendu
A., Santosh Kumar
Sahoo, Subrat Kumar
Ghosh, Sunil K.
Mane, Sushant
Dash, Arun
Charoo, Bashir Ahmad
Tripathy, Bikasha Bihary
G., Rajendra Prasad
S, Harish Kumar
K, Jothilakshmi
Sarkar, Nihar Ranjan
Arunachalam, Pavai
Mohapatra, Satya Sundar G.
Garge, Saurabh
… (more) - Abstract:
- Abstract: Background: An association between rotavirus vaccination and intussusception has been documented in post-licensure studies in some countries. We evaluated the risk of intussusception associated with monovalent rotavirus vaccine (Rotavac) administered at 6, 10 and 14 weeks of age in India. Methods: Active prospective surveillance for intussusception was conducted at 22 hospitals across 16 states from April 2016 through September 2017. Data on demography, clinical features and vaccination were documented. Age-adjusted relative incidence for 1–7, 8–21, and 1–21 days after rotavirus vaccination in children aged 28–364 days at intussusception onset was estimated using the self-controlled case-series (SCCS) method. Only Brighton Collaboration level 1 cases were included. Results: Out of 670 children aged 2–23 months with intussusception, 311 (46.4%) children were aged 28–364 days with confirmed vaccination status. Out of these, 52 intussusception cases with confirmed receipt of RVV were included in the SCCS analysis. No intussusception case was observed within 21 days of dose 1. Only one case occurred during 8–21 days after the dose 2. Post-dose 3, two cases in 1–7 days and 7 cases during 8–21 days period were observed. There was no increased risk of intussusception during 1–7 days after the doses 1 and 2 (zero cases observed) or dose 3 (relative incidence [RI], 1.71 [95% confidence interval {CI} 0.0–5.11]). Similarly, no increased risk during 8–21 days after the dose 1Abstract: Background: An association between rotavirus vaccination and intussusception has been documented in post-licensure studies in some countries. We evaluated the risk of intussusception associated with monovalent rotavirus vaccine (Rotavac) administered at 6, 10 and 14 weeks of age in India. Methods: Active prospective surveillance for intussusception was conducted at 22 hospitals across 16 states from April 2016 through September 2017. Data on demography, clinical features and vaccination were documented. Age-adjusted relative incidence for 1–7, 8–21, and 1–21 days after rotavirus vaccination in children aged 28–364 days at intussusception onset was estimated using the self-controlled case-series (SCCS) method. Only Brighton Collaboration level 1 cases were included. Results: Out of 670 children aged 2–23 months with intussusception, 311 (46.4%) children were aged 28–364 days with confirmed vaccination status. Out of these, 52 intussusception cases with confirmed receipt of RVV were included in the SCCS analysis. No intussusception case was observed within 21 days of dose 1. Only one case occurred during 8–21 days after the dose 2. Post-dose 3, two cases in 1–7 days and 7 cases during 8–21 days period were observed. There was no increased risk of intussusception during 1–7 days after the doses 1 and 2 (zero cases observed) or dose 3 (relative incidence [RI], 1.71 [95% confidence interval {CI} 0.0–5.11]). Similarly, no increased risk during 8–21 days after the dose 1 (zero cases observed), dose 2 (RI, 0.71 [95% CI, 0.0–3.28]) or dose 3 (RI, 2.52 [95% CI, 0.78–5.61]). The results were similar for 1–21 day periods after the doses separately or pooled. Conclusions: The risk of intussusception during the first 21 days after any dose of rotavirus vaccine (Rotavac) was not higher among the Indian infants than the background risk, based on limited SCCS analysis of 52 children. … (more)
- Is Part Of:
- Vaccine. Volume 39:Issue 1(2021)
- Journal:
- Vaccine
- Issue:
- Volume 39:Issue 1(2021)
- Issue Display:
- Volume 39, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 39
- Issue:
- 1
- Issue Sort Value:
- 2021-0039-0001-0000
- Page Start:
- 78
- Page End:
- 84
- Publication Date:
- 2021-01-03
- Subjects:
- Intussusception -- Rotavirus vaccine -- Vaccine safety -- Self-controlled case-series -- Rotavac -- Infant -- India
CRF Case record form -- CAC Case Adjudication Committee -- CI Confidence interval -- ICD International Classification of Diseases -- IQR Interquartile range -- LMIC Low and middle income countries -- MIC Middle income countries -- NIP National immunization programmes -- SCCS Self-controlled case series -- RI Relative incidence -- RR Relative risk -- RV1 Monovalent rotavirus vaccine (Rotarix™) -- RV5 Pentavalent rotavirus vaccine (Rotateq™) -- RVV Rotavirus vaccine -- TAG Technical Advisory Group -- WHO World Health Organization
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2020.09.019 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15001.xml